The Conventional and Alternative Pain Treatment Market was valued at USD 96.2 billion in 2024, and is projected to reach USD 144.2 billion by 2029, rising at a CAGR of 8.40%.
The devices segment, which held a 36.6% share of the overall market in 2023, is expected to grow at a CAGR of 6.7%. The growth rate of this segment is attributed to factors such as the robust use of transcutaneous electrical nerve stimulation (TENS), spine stimulators and other electric impulse devices in North America, Europe, Latin America, the Middle East and most of the developed countries within the Asia-Pacific and Africa. The growth of the conventional and alternative pain treatment market can also be attributed to the growing number of physical procedures being performed in clinics and rehabs. The rise in demand for new drugs, cannabis drugs and other alternative devices is likely to drive the market.
In this analysis, the conventional and alternative pain treatment market is segmented based on pain management type into pharmaceuticals/drug therapy and devices. The pharmaceuticals/drug therapy segment is further segmented into non-narcotic analgesics, medical cannabis, narcotic analgesics, antimigraine agents, central nervous system (CNS) treatments, anesthetics, and other classes of pharmaceutical drug therapy. The devices segment of the conventional and alternative pain treatment market is further segmented into spine stimulators, electrotherapy/muscle stimulation, and other devices. Based on application, the overall conventional and alternative pain treatment market is segmented into orthopedic and musculoskeletal pain, general and broad pain management, surgical pain management, migraine/headache pain, neuropathic pain, cancer pain, fibromyalgia pain, and other pain types.
The overall conventional and alternative pain treatment market has also been segmented by geography into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa (MEA). Each regional analysis covers the region's leading countries, namely, the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico and GCC countries. Market data is provided for 2023, which serves as the base year; estimates are given for 2024 and forecast values for 2029.
The devices segment, which held a 36.6% share of the overall market in 2023, is expected to grow at a CAGR of 6.7%. The growth rate of this segment is attributed to factors such as the robust use of transcutaneous electrical nerve stimulation (TENS), spine stimulators and other electric impulse devices in North America, Europe, Latin America, the Middle East and most of the developed countries within the Asia-Pacific and Africa. The growth of the conventional and alternative pain treatment market can also be attributed to the growing number of physical procedures being performed in clinics and rehabs. The rise in demand for new drugs, cannabis drugs and other alternative devices is likely to drive the market.
Report Scope
This report covers the conventional and alternative pain treatments used by patients with chronic or acute pain. It provides the current and future market potential of conventional and alternative pain treatments and includes a detailed analysis of the competitive environment. The report covers the drivers, restraints and opportunities in the market; surveys the prevalence of or incidence of chronic diseases; and highlights emerging technologies for alternative treatment procedures. It includes market projections for 2029 and provides the market shares of key players.In this analysis, the conventional and alternative pain treatment market is segmented based on pain management type into pharmaceuticals/drug therapy and devices. The pharmaceuticals/drug therapy segment is further segmented into non-narcotic analgesics, medical cannabis, narcotic analgesics, antimigraine agents, central nervous system (CNS) treatments, anesthetics, and other classes of pharmaceutical drug therapy. The devices segment of the conventional and alternative pain treatment market is further segmented into spine stimulators, electrotherapy/muscle stimulation, and other devices. Based on application, the overall conventional and alternative pain treatment market is segmented into orthopedic and musculoskeletal pain, general and broad pain management, surgical pain management, migraine/headache pain, neuropathic pain, cancer pain, fibromyalgia pain, and other pain types.
The overall conventional and alternative pain treatment market has also been segmented by geography into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa (MEA). Each regional analysis covers the region's leading countries, namely, the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico and GCC countries. Market data is provided for 2023, which serves as the base year; estimates are given for 2024 and forecast values for 2029.
The report includes:
- 48 data tables and 56 additional tables
- Analysis of the global market for conventional and alternative pain treatments
- Analyses of global market trends, with market revenue data from 2012-2023, estimates for 2024, and projected CAGRs through 2029
- Estimate of the current market size and revenue prospects of the global market, along with a market share analysis by pain management type, application and region
- Facts and figures pertaining to the market dynamics, technological advances, regulations, and the influence of macroeconomic factors
- A Porter's Five Forces analysis, a global supply chain analysis and a SWOT analysis
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
- A look at recent patent grants
- Analysis of the industry structure and competitive landscape, including company market shares, strategic alliances, M&A activity and venture funding outlook
- Profiles of market leaders, including: Medtronic, Abbott, GSK, Pfizer Inc., and Johnson & Johnson
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview of Types of Pain and Its Treatment
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies and Developments
Chapter 5 Market Segmentation Analysis
Chapter 6 Competitive Intelligence
Chapter 7 Sustainability
Chapter 8 Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott
- AbbVie Inc.
- Amgen Inc.
- Baxter
- Bayer AG
- Boehringer Ingelheim International GmbH
- Boston Scientific Corp.
- GSK PLC
- Johnson & Johnson Services Inc.
- Lilly
- Medtronic
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 173 |
Published | November 2024 |
Forecast Period | 2024 - 2029 |
Estimated Market Value ( USD | $ 96.2 Billion |
Forecasted Market Value ( USD | $ 144.2 Billion |
Compound Annual Growth Rate | 8.4% |
Regions Covered | Global |
No. of Companies Mentioned | 15 |